Hosted on MSN2mon
Hansa Biopharma announces success in Guillain-Barré Syndrome trialGBS is an immune disorder ... strength was 10.7 points as assessed by the Medical Research Council (MRC) sum score. When compared with results from the IGOS real-world comparator group, patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback